Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.16 (market cap $140.85M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 52.2× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KOLD | SYRE | |
|---|---|---|
Market Cap | $140.85M | $7.35B |
Volume | 6,606,542 | 1,624,631 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $108.92 |
52-Week Low | $13.58 | $22.18 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock shows significant selling pressure with 16 sell signals versus 1 buy signal across technical indicators. Natural gas market fundamentals remain challenging with record-high U.S. production reported by the EIA in July 2026, while geopolitical tensions in the Middle East create volatility in energy markets.
The outlook remains cautious as technical indicators point to continued downward momentum. Investment opportunities exist for contrarian investors given the oversold RSI reading, but risks include persistent natural gas price weakness and high production levels that may pressure energy sector performance in the near term.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
